Incyte has announced positive topline data from the Phase III inMIND trial evaluating its CD19-targeting monoclonal antibody Monjuvi (tafasitamab) in patients with relapsed or refractory (r/r) follicular lymphoma.

AbbVie and Genmab’s bispecific antibody Epkinly (epcoritamab) can now be used to treat patients with relapsed or refractory follicular lymphoma, based on an FDA approval on Wednesday.

AbbVie and Genmab have reported data from the Phase I/II EPCORE NHL-1 clinical trial of T-cell engaging bispecific antibody epcoritamab (DuoBody CD3xCD20) in adults with relapsed/refractory (r/r) follicular lymphoma (FL).

Positive topline results were announced for the relapsed/refractory follicular lymphoma (FL) cohort of the Phase I/II EPCORE NHL-1 trial evaluating Genmab and AbbVie’s Epkinly (Epcoritamab-bysp).

Novartis NVS announced that the FDA has approved a label expansion of its CAR-T cell therapy Kymriah (tisagenlecleucel).